Biosortia Pharmaceuticals

Biosortia Pharmaceuticals is a private, pre-revenue biotech firm pioneering industrial-scale microbiome mining to unlock novel small molecules from aquatic environments. Founded in 2015 and based in San Diego, the company's core technology platform involves harvesting, sequencing, and screening complex microbiomes to create a proprietary database and compound library for out-licensing and collaboration. With a leadership team experienced in innovation and IP, Biosortia aims to become a premier source of novel natural products for drug discovery, targeting rare diseases and multiple adjacent industries, though it faces significant technical and commercial risks inherent in early-stage platform companies.

Industrial-scale microbiome mining platform for harvesting, sequencing, and screening aquatic microbiomes to discover novel small molecules and generate exclusive datasets for AI-driven drug discovery.

Biosortia competes with other natural product discovery companies (e.g., Lodo Therapeutics, Hexagon Bio) and broader drug discovery platform technologies, including synthetic library screening, DNA-encoded libraries, and computational design. Its differentiation lies in its specific focus on intact aquatic microbiomes and its integrated, industrial-scale harvesting-to-dataset platform.